Beijing Mayor Visited Sinovac on Promoting Development of Biopharmaceutical Industry

2009-04-27

In the morning of April 22^nd, 2009, Beijing government officers , Qi Liu, Jinlong Guo, Anshun Wang, Shixiang Li, Fengtong Zhao, Zhongwen Gou, Xiangyang Ding and other officers from relative governmental departments, total more than 40 governors, came to Sinovac to perform the specific research related to “Improve the capability of independent innovation and promote the development of biopharmaceutical industry” on pharmaceutical industry and academic organizations. They were accompanied by the head of Administrative Committee of Zhongguancun Science Park, Wei Dai, the head of Haidian Chinese Communist Party Committee, Weike Tan, the head of Haidian District Government, Fusheng Lin, etc.

In the filling & packaging plant of Sinovac, officers inspected two modern packaging lines and learned the manufacturing process. Sinovac CEO, Weidong Yin reported Sinovac’s R&D and industrialization projects to these officers, and introduced the situation of current operation and future development plan as well as the focus of investment under the economic crisis. Weidong Yin said, “Developing towards an enterprise group is our goal. We have to contribute our efforts to the aim of Beijing development.

After reporting, Qi Liu and other government officers discussed with Weidong Yin about building up Zhongguancun National Innovation Park, the tax policy about companies’ re-investment and the development of biopharmaceutical industry.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.